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 This Clinical Practice Guideline provides key recommendations on the 
management of soft tissue and visceral sarcomas. 
 Recommendations have been agreed following a consensus meeting of 
representatives from ESMO, EURACAN and GENTURIS. 
 Authorship includes a multidisciplinary group of experts from different 














Soft tissue sarcomas (STSs) comprise approximately 80 entities defined by the 
World Health Organization (WHO) classification based on a combination of 
distinctive morphological, immunohistochemical and molecular features.1 These 
ESMO-EURACAN-GENTURIS (European Society for Medical Oncology; European 
Reference Network for Rare Adult Solid Cancers; European Reference Network for 
Genetic Tumour Risk Syndromes) Clinical Practice Guidelines (CPGs) will cover 
STSs, with the exception of gastrointestinal stromal tumours (GISTs) that are 
covered in the ESMO-EURACAN-GENTURIS GIST CPGs.2 EURACAN and 
GENTURIS are the European Reference Networks connecting European institutions, 
appointed by their governments, to cover rare adult solid cancers and genetic cancer 
risk syndromes, respectively. Extraskeletal Ewing sarcoma, round cell sarcoma with 
EWSR1-non-ETS fusion, and sarcomas with CIC-rearrangements and BCOR 
genetic alterations are covered by the ESMO-EURACAN-GENTURIS-ERN PaedCan 
(European Reference Network for Paediatric Oncology) bone sarcomas CPG.3 
Kaposi’s sarcoma, embryonal and alveolar rhabdomyosarcoma are not discussed in 
this manuscript, while pleomorphic rhabdomyosarcoma is viewed as a high-grade, 
adult-type STS. Finally, extraskeletal osteosarcoma is also a considered a high-
grade STS, whose clinical resemblance with osteosarcoma of bone is doubtful. The 
methodology followed during the consensus is specified at the end of the manuscript 
in a dedicated paragraph.  
 
INCIDENCE AND EPIDEMIOLOGY 
Adult-type soft tissue and visceral sarcomas (excluding GISTs) are rare tumours, 
with an estimated incidence averaging 4-5/100,000/year in Europe.4 The most 
common STS types are liposarcomas and leiomyosarcomas (LMSs), with an 
incidence <1/100,000/year each, while the majority of sarcoma histotypes have an 
incidence <2/1,000,000/year. 
 
Management in specialist reference centres 
STSs can occur at any site in the body and are often managed with multimodal 
treatments. A multidisciplinary approach is, therefore, mandatory in all cases, 










radiation oncologists, medical oncologists and paediatric oncologists, as well as 
nuclear medicine specialists and organ-based specialists, as applicable. 
Management should be carried out in reference centres for sarcomas and/or within 
reference networks sharing multidisciplinary expertise and treating a high number of 
patients annually.5 These centres are involved in ongoing clinical trials, in which the 
enrolment of sarcoma patients is common practice. Referral to a specialist centre 
should occur early at clinical diagnosis of a suspected sarcoma. This would mean 
referring all patients with an unexplained deep soft tissue mass, or with a superficial 
soft tissue lesion with a diameter ≥5 cm. Quality criteria are needed for sarcoma 
reference centres and, increasingly, reference networks. These criteria may vary 
between countries but should be based on: multidisciplinarity (incorporating tools 
such as weekly multidisciplinary sarcoma tumour board meetings discussing cases), 
case volume, availability of facilities needed to properly apply CPGs, access to state-
of-the-art diagnostic molecular pathology, recording and publication of outcomes and 
involvement in clinical and translational research.6 
 
Recommendation 
 Management of STS should be carried out in sarcoma reference centres or 
tertiary paediatric oncology centres as appropriate for age [III, A]. 
 
DIAGNOSIS AND PATHOLOGY/MOLECULAR BIOLOGY 
In primary soft tissue tumours, magnetic resonance imaging (MRI) is the main 
imaging modality in the extremities, pelvis and trunk. Standard radiographs may be 
useful to rule out a bone tumour, to detect bone erosion with a risk of fracture and to 
show calcifications. Computed tomography scan (CT) has a role in calcified lesions, 
to rule out a myositis ossificans, in pleuro-pulmonary sarcomas, and in 
retroperitoneal sarcomas (RPSs) where the performance is identical to MRI. 
Ultrasound may be used as first-line imaging, but if there is any suspicion for STS it 
should be followed by a CT or MRI. 
 
Following appropriate imaging assessment, the standard approach to diagnosis 
consists of multiple, core needle biopsies, possibly by using ≥14-16 G needles. 










lesions. An open biopsy may be another option in selected cases, when decided 
within reference centres. An immediate evaluation of tissue viability using frozen-
section technique may be considered to ensure that the biopsy is adequate and 
representative at the time it is carried out, although an immediate diagnosis is not 
encouraged, because frozen section does not allow a complete diagnosis. A biopsy 
may underestimate the tumour malignancy grade. Therefore, when preoperative 
treatment is an option, radiological imaging [including 18F-fluorodeoxyglucose 
positron emission tomography/CT (FDG-PET/CT)] may be useful, in addition to 
pathology, in providing information that helps to estimate the malignancy grade. The 
biopsy should be carried out by a surgeon or a radiologist after multidisciplinary 
discussion. It should be planned in such a way that the biopsy tract and the scar can 
be safely removed by definitive surgery (except for RPSs). The biopsy entrance point 
can be tattooed. Even if formalin-fixed paraffin-embedded (FFPE) material allows 
routine molecular diagnostics, the collection of fresh snap-frozen tissue is 
encouraged to allow subsequent molecular assessments, particularly in the context 
of research. Informed consent for biobanking should be sought, enabling later 
research.  
 
Pathological diagnosis should be made according to the 2020 WHO classification for 
soft tissue and bone tumours.1 Since discrepancy rates between diagnosis made 
outside of reference centres and those made by a sub-specialised bone and soft 
tissue pathologist are considerable, (ranging from 8%-11% for major discordance, 
and 16%-35% for minor discordance), a pathological expert validation is required in 
all cases when the original diagnosis is made outside a reference centre/network.7 
 
The International Collaboration for Cancer Reporting (ICCR) provides guidelines for 
standardised pathology reporting of STS (Supplementary Table S1).8 The tumour 
grade should be provided in all cases in which this is feasible and applicable based 
on available systems because it has prognostic and predictive meaning. The 
Fédération nationale des centres de lutte contre le cancer (FNCLCC) grading system 
is generally used, which distinguishes three malignancy grades based on 
differentiation, necrosis and mitotic rate.9 Whenever possible, the mitotic rate should 










chemotherapy (ChT) and/or radiotherapy (RT), as the tumour tissue undergoes 
therapy-related changes. 
 
The pathology report following definitive surgery should include whether the tumour 
was intact and the status of surgical margins. If margins are involved, a distinction is 
made between macroscopic complete resection with microscopic involvement (R1) 
and macroscopic incomplete resection (R2).9 In case of negative margins (R0), the 
minimum that should be documented is the distance of tumour to the closest 
margins. The type of tissue comprising the resection margin should also be recorded 
since specific tissue types (e.g. fascia) might provide more robust margins than 
others. In retroperitoneal liposarcomas, microscopic surgical margins have limited 
clinical value.  
 
If preoperative treatment was administered, the pathology report should include an 
assessment of the pathological response, even though no validated system for 
pathological response assessment are available for STS. A multidisciplinary 
judgement is recommended, involving the pathologist and the radiologist. Preferably, 
post-treatment resection specimens are grossly worked up in a standardised manner 
as described by the European Organisation for Research and Treatment of Cancer 
(EORTC) consensus group.10 At the very least, the pathologist should document the 
microscopic proportion of viable/residual tumour cells.10 It is advised also to 
document the percentage of fibrosis/hyalinisation even though the prognostic role of 
these parameters is still left to be investigated. 
 
Pathological diagnosis relies on morphology complemented by 
immunohistochemistry and/or molecular pathology. Pathology diagnosis should be 
complemented by molecular pathology, especially when: 
 The specific pathological diagnosis is doubtful. 
 The clinical pathological presentation is unusual. 
 It may have prognostic and/or predictive relevance, as exemplified by 










 The labels of the entity specifically refer to a distinctive molecular aberration. 
External quality assurance programmes are mandatory for laboratories 
performing molecular pathology assessments. 
 
Recommendation 
 Pathological diagnosis should be made by a sarcoma expert pathologist 
according to the 2020 WHO classification [IV, A]. 
 
STAGING AND RISK ASSESSMENT 
Available staging classifications have limited relevance and should be improved. The 
Union for International Cancer Control (UICC) stage classification system, 8th edition 
stresses the importance of the malignancy grade in sarcoma.11 Other prognostic 
factors are tumour size, tumour site, tumour resectability, the presence of 
metastases, quality of surgical margins and preoperative/intraoperative tumour 
rupture. Validated nomograms are available, which can help personalise risk 
assessment and aid clinical decision making, especially regarding the benefit of 
adjuvant/neoadjuvant treatments.12-14 
 
A CT of the thorax is recommended for staging purposes. Regional lymph node (LN) 
metastases are usually rare (i.e. <1%); there are exceptions like epithelioid sarcoma, 
clear cell sarcoma (CCS), synovial sarcoma and angiosarcoma, for which regional 
assessment through CT/MRI may be added to the usual staging procedures. A CT of 
the abdomen and pelvis is recommended in the majority of sarcoma types, 
especially myxoid liposarcoma (MLS) and LMS [III, B]. Alternatively, a whole-body 
MRI can also be considered. Imaging of the brain (MRI preferred over CT) should be 
carried out in alveolar soft part sarcoma (ASPS) and can be considered for CCS and 
angiosarcoma.  
FDG-PET/CT may be reserved as a problem-solving tool, for example for 
characterising equivocal CT findings such as LNs in relevant sarcoma types. Studies 
on cost-effective staging procedures are required. 
 
The surgical report, or patient chart, should provide details on preoperative and 










it should mention whether tumour rupture occurred either before or during surgery), 
the actual completeness and planned quality of margins. 
 
Germline TP53 testing 
Germline TP53 testing should be carried out, if possible, before treatment initiation in 
(i) patients with STS under 46 years of age and at least one 1st or 2nd degree 
relative with a TP53 core tumour (breast cancer, STS, bone sarcoma, central 
nervous system tumour, adrenocortical carcinoma) under 56 years of age, or (ii) 
patients with STS (especially in RT fields) and another TP53 core tumour under 46 
years of age.15 In TP53 carriers, RT should be avoided if possible after 
multidisciplinary discussion,15 while an annual whole-body MRI is recommended.15 
 
Recommendations  
 Available staging classifications (UICC-AJCC) are of limited clinical value. 
Risk assessment is better obtained through the available nomograms [IV, A]. 
 Staging is routinely performed with contrast enhanced CT chest, abdomen 
and pelvis. Whole body MRI may be an alternative, especially in selected 
histotypes. Brain CT/MRI may be indicated only in ASPS, CCS and 
angiosarcoma. FDG-PET/CT is indicated as a problem-solving tool in 
equivocal cases [IV, A]. 
 Surgical report should include preoperative and intraoperative diagnosis, 
possible contamination/tumour rupture, completeness and planned quality of 
microscopic margins [IV, A]. 
 TP53 testing should be carried out in selected patients with STS under the 
age of 46. [IV, A]. 
 
MANAGEMENT OF LOCAL/LOCOREGIONAL DISEASE  
This paragraph focuses on STSs arising from extremities and trunk walls (including 
paraspinal and head and neck locations). Special considerations about specific sites 
and histological types will appear later in the document. Management of 
local/locoregional disease located in an extremity or superficial trunk is summarised 
in Figures 1 and 2. Surgery is the standard treatment for all patients with an adult-










treatment of this disease within a sarcoma centre/network. The standard surgical 
procedure is an en bloc excision with R0 margins. This implies removing the tumour 
in a single specimen with a rim of normal tissue around it [II, A].16 The minimal 
margin on fixed tissue to be considered adequate may depend on several factors, 
including histological subtype, preoperative therapies and the presence of resistant 
anatomical barriers, such as muscular fascia, vascular adventitia, periosteum and 
epineurium. As an individualised option, R1 excision can be acceptable in carefully 
selected cases, in particular marginal excisions along the pseudo-capsule are 
advised for atypical lipomatous tumours. [IV, B].  
 
RT is typically added to surgery as part of the standard treatment of high-grade (G2-
3) lesions [II, B].17, 18 While historically RT was preferably delivered postoperatively, it 
is now often delivered in the preoperative setting. RT is not indicated in the case of a 
truly compartmental resection of a tumour entirely contained within the compartment 
[IV, E]. RT may also be omitted after multidisciplinary discussion, considering risk 
factors for local recurrence, including expected/actual surgical margins, tumour size 
and histological type.19 This also applies to low-grade STS, which are mostly treated 
by surgery alone, but preoperative or postoperative RT can be considered on an 
individualised basis factoring histological type, tumour size and site, as well as the 
consequences of a local recurrence. 
 
Local control and overall survival (OS) are not influenced by the timing of RT. 
However, preoperative RT is able to offset the negative prognostic impact of R1 
margins much more than postoperative RT. It should always be considered when 
preservation of a critical structure is the goal.20, 21 Early complications (wound 
complications) are more common after preoperative RT, but long-term morbidity is 
improved with a reduction in fibrosis, oedema, bone fracture and joint stiffness.22 RT 
should be delivered with the most appropriate technique available (including but not 
limited to intensity-modulated RT (IMRT) and particle therapy in challenging sites), to 
a total dose of 50 Gy in 1.8-2 Gy fractions in the preoperative setting. In the 
postoperative setting, doses up to 66 Gy are given, depending on presentation, age 
and resection margins. Neoadjuvant RT can be given in combination with ChT to the 
same total dose of 50 Gy in 1.8-2 Gy fractions with manageable toxicity.23 Surgery 










fraction of RT. With modern RT techniques, such as image-guided RT and IMRT, the 
anticipated incidence of wound complications after preoperative RT may be lower 
than historically published incidence rates. Short-course preoperative regimens with 
hypofractionation have been recently reported, showing comparable effects to 
conventional fractionations.24  
 
Histological types such as MLS, solitary fibrous tumour (SFT), myxofibrosarcoma, 
and extraskeletal myxoid chondrosarcoma (EMC) gain the greatest benefit from 
RT.25, 26 For MLS, one study has recently investigated a low dose (18x2 Gy), 
showing activity of the reduced regimen, but without comparing the efficacy with 
conventional doses.27 Re-excision at reference centres must be considered in case 
of unplanned resections if adequate margins can be achieved without major 
morbidity, while taking into account tumour extent and tumour biology [e.g. a re-
excision can be spared in atypical lipomatous tumours and classic 
dermatofibrosarcoma protuberans (DFSP)] [IV, A]. In case of R2 surgery, 
reoperation at reference centres is mandatory, possibly following preoperative 
treatments if adequate margins cannot be achieved, or if surgery is mutilating. When 
surgery may be mutilating, a multimodal treatment employing less radical surgery is 
an option and requires shared decision-making with the patient. Plastic surgery 
reconstruction and vascular grafting should be utilised as needed, and the patient 
should be properly referred if necessary. 
 
When re-excision is not possible after R1-R2 resections, postoperative RT may be 
considered, tailoring the decision depending on further considerations, including the 
impact on future surgeries. 
 
Amputation may be the only option in certain cases. Options for limb-preserving 
surgery can be discussed with the patient, including ChT and/or RT [III, A], or 
isolated limb perfusion (ILP) with tumour necrosis factor-α (TNF-α) plus melphalan 
[III, A]. Perioperative regional hyperthermia combined with ChT is another option [I, 
B].28 These options are considered in non-resectable tumours as well.  
 
Regional LN metastases should be distinguished from soft tissue metastases in a 










adverse prognostic factor. More aggressive multimodality treatment may be 
appropriate for patients with locoregional recurrences including LN metastases, 
although there is a lack of formal evidence of a benefit. Radical surgery may be 
combined with neoadjuvant RT and neoadjuvant ChT for sensitive histological types 
[IV, B]. ChT may be administered as preoperative treatment, at least in part, 
especially in chemo-naïve patients. ILP may be an option when easy limb- or 
function-sparing surgery is not possible. This modality has no impact on systemic 
control (but it can be combined with other modalities) [III, A].29 
 
In operable, localised STSs of extremities and the trunk wall, there is no uniform use 
of adjuvant and neoadjuvant anthracycline plus ifosfamide (AI) ChT amongst expert 
centres. Formally, adjuvant and neoadjuvant AI ChT is not a standard treatment. 
However, it can be proposed with fit patients affected by disease at high-risk of 
death. While published clinical controlled trials are conflicting and some large trials 
have shown no benefit from adjuvant and neoadjuvant AI ChT, smaller controlled 
trials and subgroup analyses of larger trials have provided data suggesting that 
when the risk of death is high, neoadjuvant or adjuvant AI ChT may improve relapse-
free survival (RFS) and OS.30-32 
 
Risk predicting tools such as Sarculator have identified a threshold of risk above 
which the administration of AI ChT may provide statistically and clinically significant 
benefits [II, B].12, 33 These tools apply to the most common histological types. 
Patients affected by these types and with a 10-year predicted OS <60% should be 
selected. ChT should preferably be given in the neoadjuvant setting for at least three 
courses, given the non-inferiority of this shorter regimen compared to five cycles, 
shown in a randomised study [II, B].34 The decision in patients affected by less 
common types needs to be made on an individual basis. Histological types known to 
be refractory to AI ChT in the metastatic setting (such as ASPS, CCS) should not 
receive adjuvant/neoadjuvant ChT.   
 
During neoadjuvant ChT the tumour behaviour should be monitored to exclude 
progression, while considering possible patterns of non-dimensional tumour 
response. During neoadjuvant ChT-RT, RT should not delay the beginning of ChT, 










tolerability of the combination [III, B].23 In MLS, data from one trial suggest that 
trabectedin may be an alternative to AI. Evidence has also been provided on the 
safety profile of its combination with RT. In angiosarcoma, adjuvant/neoadjuvant 
ChT may be a reasonable option, since there is a high-risk of local and metastatic 
relapse and the sensitivity to available agents (i.e. anthracyclines, ifosfamide, 
taxanes, gemcitabine) is high. However, definitive evidence to support this is 
currently lacking.   
 
For the use of adjuvant or neoadjuvant ChT for STSs arising from primary sites other 
than limbs and superficial trunk, as well as for histologies not covered by available 
studies, a shared patient decision making along with multidisciplinary tumour board 
discussion should be engaged. 
 
In one large randomised phase III study (in patients with G2-3, deep, >5 cm STS), 
regional hyperthermia in addition to systemic ChT was associated with better 
response rates, a longer local progression-free survival (PFS), disease-free survival 
(DFS) and OS advantage [I, B].28 
 
In general, adjuvant ChT should never be intended to compensate for inadequate 
surgery.  
 
The standard approach to local relapses parallels the approach to primary local 
disease, except for a wider utilisation of preoperative or postoperative RT and/or 
ChT, if not previously administered.  
 
Recommendations 
 Surgery is the standard treatment of all patients with an adult-type, localised 
STS. It must be carried out by a surgeon specifically trained in the treatment 
of STSs. The standard surgical procedure is an en bloc wide excision with R0 
margins [II, A]. 
 Wide excision and RT are the standard treatment of high-grade (G2–3) 
lesions [II, B]. The sequence of the two treatments varies among institutions, 










when preserving a critical structure is one of the goals. RT can be omitted 
only after multidisciplinary discussion in reference centres considering several 
variables. 
 Options for limb-preserving surgery include ChT and/or RT [III, A], or ILP [III, 
A], or regional hyperthermia combined with ChT [I, B]. 
 Adjuvant/Neoadjuvant AI ChT for at least three cycles can be proposed to 
patients at high-risk of death [II, B]. 
 Neoadjuvant ChT with regional hyperthermia is another individualised option 
in patients at high-risk of death [I, B].  
 
MANAGEMENT OF ADVANCED DISEASE  
Management of advanced disease is summarised in Figures 3 and 4. When 
managing patients with advanced/metastatic STS, the decision-making is complex, 
depending on the diverse presentations and histologies, and should always be 
multidisciplinary. Metachronous (disease-free interval ≥1 year), resectable lung 
metastases without extrapulmonary disease are managed with surgery as standard 
treatment, if complete excision of all lesions is feasible, taking into account all 
prognostic factors [IV, B].35 A minimally invasive thoracoscopic approach can be 
used in selected cases. Other appropriate local techniques can be considered, 
although surgery is the standard and outcome data are required on alternative, less 
invasive options. When surgery of lung metastases is selected, an abdominal CT 
and a bone scan or an FDG-PET are mandatory to confirm that lung metastases are 
‘isolated’.  
 
ChT may be added to surgery as an option, taking into account the prognostic 
factors (a short previous recurrence-free interval and a high number of lesions are 
adverse factors, encouraging the addition of ChT), although there is a lack of formal 
evidence that this improves outcome [IV, B]. ChT is preferably given before surgery 
to assess tumour response and modulate treatment. When lung metastases are 
synchronous, in the absence of extrapulmonary disease, standard treatment is ChT 
[III, B]. Surgery for resectable residual lung metastases may be offered as an option 










metastases other local treatments, such as stereo-ablative RT, may also be 
considered. 
 
Pulmonary non-resectable disease and extrapulmonary metastatic disease is treated 
with ChT as the standard of care [I, A]. Surgery or stereo-ablative RT of 
extrapulmonary metastases without ChT may be an option in selected cases, 
especially oligometastatic disease. Surgery or RT of responding metastases may be 
offered as an option, taking into consideration the site, tumour extent and natural 
history of the disease in the individual patient. 
 
In patients with locally advanced/metastatic, nonresectable disease, a systemic 
treatment with an essentially palliative intent can be proposed. Anthracycline-based 
therapy is standard first-line treatment [I, A]. There is no formal demonstration that 
multi-agent ChT is superior to single-agent ChT with doxorubicin alone in terms of 
OS. However, a higher response rate and longer PFS can be expected in a number 
of sensitive histological types according to several, although not all, randomised, 
clinical trials.36, 37 Therefore, multi-agent ChT with adequate-dose AI may be the 
treatment of choice, particularly in histological types sensitive to ifosfamide, when a 
tumour response is felt to be potentially advantageous and patient performance 
status is good [I, B]. Doxorubicin plus dacarbazine is an option for multi-agent, first-
line ChT for LMS, in which the activity of ifosfamide is far less convincing, and for 
SFT [IV, B].38, 39 
 
A phase III study compared single-agent doxorubicin with the combination of 
gemcitabine-docetaxel as an upfront treatment in advanced STS patients of all 
types. The combination failed to show any improvement in PFS and objective 
response rate (ORR) and is not recommended as first-line therapy for advanced STS 
patients [I, D]40 including uterine LMS. 
 
Angiosarcoma is highly sensitive to taxanes, which can be a treatment option in this 
histological type [III, B].41 An alternative option is gemcitabine, alone or in 











Imatinib is standard first-line medical therapy for patients with advanced DFSP [III, 
A].43 
 
NTRK inhibitors are standard treatment for those rare patients with locally-advanced 
or metastatic NTRK-rearranged sarcomas; larotrectinib ESMO-Magnitude of Clinical 
Benefit Scale (MCBS) v1.1 score 3 [III, A; ESMO-MCBS 3] entrectinib [III, A; ESMO-
MCBS v1.1 score 3].44-46 This treatment can also be considered in the preoperative 
setting, when a cytoreduction can improve morbidity and function. For NTRK-fusion 
screening, pan-NTRK immunohistochemistry has an overall sensitivity-specificity, 
which in STS is around 80%-75%.45 Molecular confirmation of NTRK rearrangement 
is therefore requested in case of positive immunohistochemistry expression.   
 
Further-line systemic therapy can be considered in fit patients with advanced STS 
and disease progression [II, B]. For unfit patients, no further active tumour-directed 
treatment may be appropriate, especially if further-line therapies have already been 
used. In general, patients with pretreated advanced STS should be considered for 
clinical trials. For patients with anthracycline-refractory disease or who are unable to 
receive an anthracycline, there are other options available, although high-ranking 
evidence is lacking: 
 
 Patients who have already received ChT may be treated with ifosfamide if they did 
not progress on it previously. High-dose ifosfamide as continuous infusion 14 days 
(∼14 g/m2) may also be an option for patients already pretreated with standard-dose 
(9 g/m²) ifosfamide [IV, C].47, 48 
 Trabectedin is an option in advanced STS from second-line. It has proved effective 
in LMS and liposarcoma49 [I, B; ESMO-MCBS v1.1 score 2]. A high antitumour 
activity has been reported especially in MLS, with a peculiar pattern of tumour 
response. Clinical benefit with trabectedin is also described in other histological 
types. In selected cases trabectedin can be also combined to RT, as evidence of 
safety and activity across different sarcoma types was provided [III, B].50 
 A randomised trial showed a benefit in PFS averaging 3 months for pazopanib given 
until progression to advanced, previously treated, STS patients (excluding 










ESMO-MCBS v1.1 score 3]. The activity of pazopanib is also demonstrated in other 
sarcoma types within prospective phase II studies, such as SFT and extraskeletal 
myxoid chondrosarcoma, in which pazopanib was administered from first-line 
therapy [III, B].52, 53 
 A randomised phase III trial showed that eribulin was superior to dacarbazine in 
patients with liposarcomas and LMSs. The median difference OS was 2 months [I, 
B], but a subgroup analysis showed that it reached 7 months in liposarcomas.54 This 
led to the regulatory approval of eribulin for liposarcomas from second-line therapy 
[II, A; ESMO-MCBS v1.1 score: 3]. An improvement in OS was particularly seen in 
the pleomorphic liposarcoma subtype.55 
 One trial showed that gemcitabine-docetaxel is more effective than gemcitabine 
alone as second- or further-line ChT, with special reference to LMS and 
undifferentiated pleomorphic sarcoma (UPS), but these data are expected in a 
second randomised trial conducted only in LMS; in both trials, toxicity was superior 
with the combination of docetaxel-gemcitabine [II, C].56 Gemcitabine showed 
antitumour activity also in LMS, angiosarcoma and epithelioid sarcomas as a single-
agent.42, 57 The combination of dacarbazine-gemcitabine was shown to improve the 
OS and PFS over dacarbazine in a randomised trial [II, B].58 
 Dacarbazine monotherapy has some activity as a second-line therapy (mostly in 
LMS and SFT).38, 39  
 Methotrexate plus vinorelbine/vinblastine were retrospectively shown to have activity 
in inflammatory myofibroblastic tumour.59 
 
Table 1 lists systemic agents that have shown activity, either preliminary or partial, in 
selected sarcoma types, and have not entered standard practice and/or they are not 
approved/reimbursed in all European countries. Thus, if available, their use may be 
considered in the clinical balance within individualised patient–physician shared 
decisions. RT should be considered as a palliative resource in all cases as 












 Standard treatment of metachronous (disease-free interval ≥1 year), 
resectable lung metastases without extrapulmonary disease is surgery, if 
complete excision of all lesions is feasible [IV, B]. 
 Standard ChT is based on anthracyclines as first-line treatment [I, A]. Multi-
agent ChT with adequate-dose AI or dacarbazine may be the treatment of 
choice, particularly in subtypes sensitive to ifosfamide or dacarbazine, when a 
tumour response is felt to be potentially advantageous and patient 
performance status (PS) is good [I, B]. 
 Gemcitabine-docetaxel is not generally recommended as a first-line therapy 
for advanced STS patients [I, D].  
 Imatinib is standard medical therapy for patients with DFSP [III, A].  
 NTRK inhibitors are standard treatment for patients with advanced NTRK-
rearranged sarcomas [III, A]. They can be considered also in the preoperative 
setting, when a cytoreduction can improve morbidity and function. [III, A; 
ESMO-MCBS v1.1 score 3]. 
 Trabectedin is an option from second-line in STS [I, B; ESMO-MCBS v1.1 
score 2].  
 Pazopanib is an option in nonadipogenic STS, from second-line [I, B; ESMO-
MCBS v1.1 score 3] 
 Eribulin is an option in patients with liposarcomas [II, A; ESMO-MCBS v1.1 
score: 3].  
 The combination of dacarbazine-gemcitabine, or gemcitabine-docetaxel is an 
option in doxorubicin-pretreated patients [II, B]. 
  
FOLLOW-UP 
There are few published data to indicate the optimal routine follow-up policy of 
surgically-treated patients with localised disease.60 
 
The tumour grade affects the likelihood and interval at which relapses may occur. 
Risk assessment based on histological type, tumour grade, size and site help in 
choosing a routine follow-up policy. High-risk patients generally relapse within 2-3 
years, whereas low-risk patients may relapse later. Relapses most often occur in the 










and CT for lung metastases is likely to pick up recurrences earlier than other 
assessment/imaging modalities. 
 
While prospective studies are needed, a practical approach in place at several 
institutions is as follows: after completion of treatment, intermediate-/high-grade 
patients may be followed every 3-4 months in the first 2-3 years, then twice a year up 
to the fifth year, and once a year thereafter; low-grade sarcoma patients may be 
followed every 6 months for the first 5 years, then annually. 
 
SPECIAL PRESENTATION AND ENTITIES 
 
Retroperitoneal sarcoma.  
Pre-treatment biopsy for pathological diagnosis should be carried out, to allow 
tailored therapeutic decisions, unless otherwise indicated by the multidisciplinary 
board. Risk of needle track seeding is minimal and should not be a reason to avoid a 
biopsy. The preferred route should be a retroperitoneal approach if technically 
possible rather than transperitoneal. Open or laparoscopic biopsies must be avoided. 
 
Comprehensive imaging evaluation is critical to accurately assess the extent of the 
tumour. Specific appreciation of the well-differentiated versus the dedifferentiated 
component(s) of liposarcoma is critical to surgical decision making. Histology-
specific nomograms for RPS patients are available, which can help personalise risk 
assessment and clinical decision making.13 
 
The best chance of curative resection is at primary presentation. The standard 
treatment of primary lesions is surgery. Surgery should be aimed at achieving a 
single en bloc specimen and macroscopically complete resection minimising R1 
margins. This is best done by resecting the tumour en bloc with adherent structures 
[III, A].61-64 Preservation of specific organs (i.e. kidney, head of the pancreas and/or 
liver, neurovascular structures, etc.) should be considered on an individualised basis. 











Grossly incomplete resection of RPSs is potentially harmful and can only be 
regarded as potentially palliative in carefully selected patients. Grossly incomplete 
resection is to be avoided by imaging review, thoughtful planning and referral to 
appropriate centres. 
 
Neoadjuvant treatment, in the form of ChT, external beam radiotherapy (EBRT), 
regional hyperthermia or combinations, can be considered in the case of technically 
unresectable/borderline resectable, i.e. RPS that could be surgically converted by 
downsizing, and in chemosensitive histologies such as synovial sarcoma.26 
 
Preoperative RT in resectable tumours did not improve RFS and OS in one 
randomised clinical trial [I, D].65 However, signals of efficacy were observed in the 
liposarcoma subgroup and low-intermediate malignancy grade. Therefore, in patients 
with a low-intermediate grade liposarcoma preoperative RT can be discussed. On 
the contrary, no effect was seen in resectable LMS and high-grade dedifferentiated 
liposarcoma. Therefore, in patients affected by these sarcoma types preoperative RT 
should not be considered.  
 
The value of preoperative RT in other rarer histological types is less established. 
However, the activity of RT in SFT should be factored into the decision.26 For all 
other histological types an individualised decision with a higher degree of uncertainty 
can be made based on size of the tumour, its local risk and the expected quality of 
surgery. 
 
Postoperative/adjuvant EBRT following complete gross resection is of limited value 
and is associated with significant short- and long-term toxicities, because a 
therapeutic RT dose can be achieved in a minority of patients. In selected cases, it 
may be an option in well-defined anatomical areas thought to be at high-risk. 
Brachytherapy is of unproven value and is associated with significant short- and 
long-term complications. Intraoperative RT is of unproven value. 
 
In a large, randomised phase III study (in patients with G2-3, deep, >5 cm STSs), 
regional hyperthermia in addition to systemic ChT was associated with PFS, DFS 











The value of adjuvant/neoadjuvant ChT is not established, though the rarity of the 
subtypes of RPSs force extrapolation of the data available in other settings.  
 
Surgery of local recurrences could be offered on an individualised basis, especially 
to patients affected by well-differentiated liposarcoma and having a long disease-free 
interval between initial resection and subsequent recurrence, and possibly to 
patients experiencing a response to medical therapies.66 
 
Uterine sarcomas.  
Uterine sarcomas include LMS, endometrial stromal sarcomas (ESSs, formerly low-
grade ESSs), undifferentiated endometrial sarcomas (UESs) and adenosarcoma 
with sarcomatous overgrowth (ASS). Carcinosarcomas (malignant Müllerian mixed 
tumours) are currently viewed as epithelial cancers, and treatment should be tailored 
accordingly. Thus, before a final diagnosis of a sarcoma is made, the pathologist 
should be certain that an epithelial component is absent. 
 
Clinical and radiological criteria to confidently differentiate leiomyomas from 
malignant uterine tumours are not available yet. Thus, procedures resulting in 
potential tumour cell spillage, such as morcellation out of endoscopic-bags, are 
discouraged because they entail a high-risk of worsening patient prognosis when 
malignancy is the post-operative pathological diagnosis.67 
 
Smooth muscle tumours of undefined malignant potential (STUMPs) constitute a 
negative definition, which is used when both leiomyoma and LMS cannot be 
diagnosed with certainty.68 There are remarkable variations with this diagnosis 
among pathologists that imply a degree of subjectivity. Some of these lesions might 
actually represent ‘low-grade’ LMS, whose existence is disputed. Due to the 
uncertainty about their prognosis, a hysterectomy is usually proposed to patients 
with a diagnosed STUMP, but there may be room for individualised decision making. 
Careful follow-up is then recommended. 
 
Standard local treatment of localised uterine LMS (U-LMS), ESS and UES is en bloc 










tumour is resected with the same criteria as for open surgery and morcellation is not 
performed). With a diagnosis of sarcoma, systematic lymphadenectomy has not 
been demonstrated to be useful. The added value of bilateral salpingo-
oophorectomy is not established, particularly in premenopausal women, so possible 
ovarian preservation is feasible. There are studies suggesting that ovarian 
preservation may be an option even in cases of International Federation of 
Gynaecology and Obstetrics (FIGO) stage I ESS.69 With a diagnosis of sarcoma, 
fertility-preserving surgery in young women should not be regarded as a standard 
procedure. In ESS, however, LNs may be positive in roughly 10% of cases. RT has 
not improved RFS and OS in the only prospective randomised trial and is not 
recommended [I, D].70 The use of postoperative RT can be an option in selected 
cases, following multidisciplinary discussion considering special risk factors, 
including: local relapse, cervical involvement, parametral involvement, serosal 
involvement and UES histology [IV, C]. Adjuvant ChT in U-LMS is not standard, 
since its value is undetermined [IV, C]. Uncontrolled studies suggested a benefit in 
comparison with external controls for four courses of gemcitabine-docetaxel followed 
by four courses of doxorubicin, as well as four courses of gemcitabine-docetaxe.71 A 
prospective, randomised trial with a no-treatment control arm versus four courses of 
gemcitabine-docetaxel followed by four courses of doxorubicin was attempted but 
closed early due to lack of accrual (International Rare Cancers Initiative (IRCI) 
001, NCT01533207).  
 
The systemic treatment of advanced U-LMS, UES and ASS parallels that for adult-
type STSs. As for all LMSs, doxorubicin, dacarbazine, trabectedin, gemcitabine 
alone or in combination with docetaxel, and pazopanib are active agents and may be 
used in a stepwise fashion. There is retrospective evidence that ifosfamide may be 
less active as a single-agent in LMS.38 
 
ESSs are histologically low-grade tumours, with a consistent pathological 
appearance. The diagnosis is supported by typical cytogenetics, marked by a 
chromosomal translocation (7;17) with JAZF1-SUZ12 or related translocations 
joining EPC1-PHF1 or JAZF1-PHF1 genes. Adjuvant hormonal therapy (HT) is not 
standard, though it may be an option, given retrospective evidence suggesting its 










hormones makes the benefit questionable overall [IV, C]. The systemic treatment of 
metastatic low-grade ESSs exploits their sensitivity to HT [V, B]. Therefore, 
progestins, aromatase inhibitors and gonadotropin-releasing hormone (GnRH) 
analogues (for premenopausal patients) can be used.67 Tamoxifen is contraindicated 
due to a possible agonist activity, as is hormonal replacement therapy containing 
oestrogens. ChT may be an option when HT has failed. Surgery of lung metastases 
is an option, even in presentations which might not be surgically approached in other 
STSs, given the long natural history of the disease. This may apply to pelvic disease 
as well, even in the presence of metastatic disease. 
 
A subgroup of high-grade ESS is recognised, which is defined by specific 
cytogenetics, marked, in most cases, by the YWHAE-FAM22 transcript.72 Other less 
common molecular alterations can be detected, including ZC3H7B-BCOR fusion and 
BCOR internal tandem duplication.1 They are often insensitive to HT, and cytotoxic 
ChT is considered appropriate in the metastatic setting, with notable responses 
reported with anthracycline-based regimens [IV, B].73 
 
High-grade ESS, adenosarcoma with sarcomatous overgrowth and UES are high-
grade malignancies. There are no data on the value of adjuvant ChT, though their 
high-risk status may justify an individualized decision especially in UES [V, C]. 
Hyperthermic peritoneal ChT has not been shown to be effective and is an 
experimental-only option. 
 
For benign metastasising leiomyomas, clinical observation is the treatment of choice 
at diagnosis, with HT (as for ESS) being standard treatment for progressing disease 
and surgery. The same applies to peritoneal leiomyomatosis if non-mutilating 
surgery is not feasible. 
 
For pelvic aggressive angiomyxoma, surgery may be the treatment of choice if not 
debilitating, with observation thereafter. In progressing disease, HT, or interruption of 
any ongoing stimulation with oestrogens, may allow mutilating surgery to be avoided 
and the disease to be kept under control.74 
 










While principles for the diagnosis of STS apply also to DF, mutational analysis of β-
catenin and the APC gene in β-catenin-negative cases may be useful when the 
pathological differential diagnosis is difficult. In patients affected by β-catenin, wild-
type DF familial adenomatous polyposis should be ruled out.  
 
Given the unpredictable natural history of the disease (with the possibility of long-
lasting stable disease and even occasional spontaneous regressions, along with a 
lack of metastatic potential) and functional problems implied by some tumour 
anatomical locations, an initial active surveillance policy can be proposed [III, A].75 
This should follow a careful monitoring of potentially life-threatening extra-abdominal 
locations (e.g. head and neck region) and intra-abdominal desmoids (mesenteric 
fibromatosis). Under such a policy, treatment is reserved for progressing cases. The 
preferred imaging modality is MRI, taking into consideration that the tumour imaging 
appearances may not be meaningful with regard to the disease evolution or patient 
symptoms. 
 
For progressing cases, the optimal strategy needs to be individualised on a 
multidisciplinary basis and may consist of further watchful waiting, systemic 
therapies, or local therapies such as percutaneous cryoablation (extra-abdominal 
cases) [IV, C] ILP (if the lesion is confined to an extremity) [IV, C], and surgery in 
favourable locations (i.e. abdominal wall) [IV, C].75 Definitive RT should be 
considered after multiple failed lines of treatment or for tumours in critical anatomical 
locations where surgery would involve prohibitive risk or functional impairment, 
especially in elderly patients [III, C].75 When a systemic therapy is chosen, available 
options include: low-dose ChT (such as methotrexate-vinblastine or methotrexate-
vinorelbine; oral vinorelbine; taxanes); sorafenib (II, B); pazopanib; imatinib; and full-
dose ChT (using regimens active in sarcomas, including liposomal doxorubicin).76-83 
In addition, also HT (tamoxifen, toremifene and GnRH analogues; aromatase 
inhibitors), non-steroidal anti-inflammatory drugs and interferon have long been used 
but no prospective studies are available to understand their real activity in this 
disease.  
 










These patients should be referred to sarcoma units and managed jointly with breast 
units. Metaplastic breast carcinomas, also known as carcinosarcomas, are epithelial 
neoplasms, whose treatment should be tailored to their mainly epithelial nature. 
 
BS encompass radiation- and non-radiation-induced sarcomas. Therefore, sarcomas 
of the skin of the breast area should be conceptually distinguished from mammary 
gland sarcomas. Angiosarcoma has a more aggressive behaviour than other 
histological types, while malignant phyllodes tumours (i.e. >10 mitoses/10 high-
power field and marked stromal overgrowth) have a 20%-30% metastatic rate.  
 
In general, breast-conserving surgery may be carried out, depending on the quality 
of margins versus the size of the tumour and the breast, along with the feasibility of 
RT in primary BS, while wide excision of the RT field and immediate plastic surgical 
reconstruction is often necessary in radiation-induced BS. In angiosarcomas of the 
mammary gland the tendency to recur is high and mastectomy (involving the 
muscular fascia and the whole previously irradiated field) is recommended in most 
cases, even in combination with postoperative RT. A targeted axillary dissection 
should be done in patients with clinically- and/or radiologically-concerning nodes, as 
the lymph node metastatic risk in angiosarcoma is higher than average (5%-15%). 
 
As far as adjuvant/neoadjuvant ChT is concerned, there is a higher degree of 
uncertainty although one may use the same principles of STS at other sites. 
Considering the high-risk of angiosarcoma to develop local and systemic relapses, 
preoperative treatments including ChT and RT may be used. Re-irradiation can be 
considered in radiation-associated angiosarcomas. 
 
Recommendations 
 Patients with suspected RPS, uterine sarcoma, DF and BS need to be 
referred to high-volume sarcoma centres [III, A]. 
 Standard treatment of RPS consists in surgical resection en bloc with 
adherent organs [V, A].  
 Neoadjuvant RT has shown signs of efficacy in primary low-/intermediate-










 Intraoperative/postoperative RT are of no proven value in RPS. The role of 
adjuvant/neoadjuvant ChT is not established yet. 
 Standard local treatment of localised U-LMS, ESSs and UESs is en bloc total 
hysterectomy [IV, A]. Adjuvant RT is not recommended [I, D].  
 Active surveillance is the first-line strategy for all newly diagnosed primary DF, 
without life-threatening presentations [III, A]. 
 For progressing DF, the optimal strategy needs to be individualised on a 
multidisciplinary basis and may even consist of the continuation of the active 
surveillance, systemic therapies, local therapies, such as percutaneous 
cryoablation, ILP (if the lesion is confined to an extremity), surgery in 
favourable locations or RT [IV, C].  
 
METHODOLOGY 
This CPG has been developed by ESMO in partnership with EURACAN-GENTURIS 
during a virtual consensus meeting which was held on 5th December 2020. The 
CPG was developed in accordance with the ESMO standard operating procedures 
for CPG development http://www.esmo.org/Guidelines/ESMO-Guidelines-
Methodology. Recommended interventions are intended to correspond to the 
‘standard’ approaches for diagnosis, treatment and survivorship on sarcomas, 
according to current consensus among the European multidisciplinary sarcoma 
community of experts. This community was represented by the members of the 
ESMO Sarcoma Faculty and experts appointed by all institutions belonging to the 
Sarcoma domain of EURACAN–GENTURIS. Experimental interventions considered 
to be beneficial are labelled as ‘investigational’. Other non-standard approaches may 
be proposed to the single patient as ‘options’ for a shared patient-physician decision 
in conditions of uncertainty, as long as some supporting evidence (though not 
conclusive) is available. Algorithms accompany the text, covering the main typical 
presentations of disease, and are meant to guide the user throughout the text. The 
relevant literature has been selected by the expert authors. An ESMO-MCBS table 
with ESMO-MCBS scores in included in Supplementary Table S2. ESMO-MCBS 
v1.1.84 was used to calculate scores for new therapies/indications approved by the 
EMA since 1 January 2016 or FDA since 1 January 2020 










by the ESMO-MCBS Working Group and validated by the ESMO Guidelines 
Committee. Levels of evidence and grades of recommendation are applied using the 
system shown in Supplementary Table S3.85 Statements without grading were 
considered justified standard clinical practice by the experts.  
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Table 1. Systemic agents associated with evidence of activity in selected 
sarcoma types.  
 
ALK, anaplastic lymphoma kinase; Choi, Choi criteria; m-PFS, median progression-
free survival; N/A, not available; ORR, overall response rate; PD-1, programmed cell 
death protein 1; PD-L1, programmed death-ligand 1; PEComa, perivascular 
epithelioid cell tumour; RECIST, Response Evaluation Criteria in Solid Tumours; 
















Figure 1. Management of localised, clinically resectable, extremity and 
superficial trunk STS. 
 
Adj, adjuvant; ChT, chemotherapy;  RT, radiotherapy; STS, soft tissue sarcoma. 
a 
Depending upon histology and anatomical location. 
b













Figure 2. Management of localised, clinically unresectable, extremity and 
superficial trunk STS. 
 













Figure 3. Management of advanced/metastatic, clinically resectable STS. 
 













Figure 4. Management of advanced/metastatic, clinically unresectable STS. 
 
ChT, chemotherapy; DTIC, dacarbazine; PR, partial response; PS, performance 




















Table 1. Systemic agents associated with evidence of activity in selected 
sarcoma types.  
  







Study type  














Crizotinib88  Inflammatory  
myofibroblastic  
tumour  
Any  ALK-positive 
patients:  50;   
ALK-negative 






Imatinib89  TGCT Any  31  
(RECIST)  
NA  Retrospective 
case-series  









Alveolar soft part 
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NA  Case reports; 
retrospective 
case-series  
Pexidartinib93  TGCT    Any  pexidartinib  
versus placebo   
39 versus 0  
(RECIST)  
NA  Phase 
III, randomise
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Sirolimus97  Epithelioid 
 Haemangio 
endothelioma  












Sorafenib99  Epithelioid 
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Localised, clinically resectable, extremity and supertfi cial trunk STS
Grade 1 Grade 2-3
Surgery
R1 resection










Optional RT if 
not given
pre-operativelya













adj ChT in 
high-riskb
Surgery
R0 resection R1 resection














Localised, clinically unresectable, extremity and superfi cial trunk STS  




















Advanced / metastatic, clinically resectable STS

























Advanced / metastatic, clinically unresectable STS
Doxorubicin [I, A]
Doxorubicin + Ifosfamide [I, B]
Doxorubicin + DTIC [IV, B]
PR/SD No PR/SD
Continue until maximum 
dose progression, 
unacceptable toxicity
Histology-driven ChTPS/SD
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